Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
|Videos|May 23, 2019
HER2+ BC: Residual Disease After Neoadjuvant Therapy
HER2+ BC: Residual Disease After Neoadjuvant Therapy
Advertisement
Case: A 49-Year-Old Woman With HER2+ Breast Cancer
H & P
- A 49-year-old woman was referred by gynecology for a mass in her right breast
- No children, menopause at age 45
- No history of cardiovascular disease, otherwise good health
- PE: revealed a woman of normal weight (BMI = 21 kg/m2), with a palpable mass in her right breast
Imaging
- Mammogram revealed 3.5-cm tumor in right breast
- CT: confirmed a tumor in right breast with no lymph node involvement
Biopsy and labs:
- Histology: ductal, grade 2
- ER(-), PR (-)
- HER2IHC: 3+
- BRCA1/2: negative
Treatment
- Diagnosed with ER/PR negativeHER2+ breast cancer; she received neoadjuvant TCH-P (docetaxel + carboplatin + trastuzumab + pertuzumab and achieved a partial response
- Residual disease of 1.5 cm after neoadjuvant therapy
- Underwent mastectomy
- After discussing with her the options for adjuvant therapy, benefits and risks of each, and her goals, she was started on ado-trastuzumab emtansine (T-DM1)
- At present, she has completed 3 cycles of T-DM1
- Reports numbness in her fingers, “like wearing gloves” that sometimes interferes with small tasks like buttoning a shirt
Advertisement
Related to this article
Claire K. Mulvey, MD, explains how patient-reported outcomes and QOL assessments reveal NEN symptom burden and help guide treatment.
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Liver transplant led to durable survival in unresectable NET liver metastases; tumor burden predicted outcomes, and recurrence was common but treatable.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Erica S. Alexander, MD, highlights endovascular approaches to venous occlusion, including stenting and thrombolysis, for select patients with NETs.
Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.
In a phase 1 trial, a single intratumoral injection of oncolytic virus SVV-001 with ipilimumab and nivolumab was safe in high-grade neuroendocrine cancers.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zocilurtatug Pelitecan Shows Activity in epNEC Across DLL3 Expression Levels
3
Dr Mohamed on Zocilurtatug Pelitecan for Refractory Extrapulmonary NEC
4
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
5